Sofinnova Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

Sofinnova Investments’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-176,181	Closed	-$47.6M	–	65
2025 Q1	$47.6M	Buy	176,181 +66,024	+60%	+$17M	3.11%	8
2024 Q4	$25.9M	Buy	+110,157	New	+$29M	1.89%	17
2024 Q3	–	Sell	-147,929	Closed	-$35.9M	–	64
2024 Q2	$35.9M	Buy	147,929 +44,893	+44%	+$7.09M	1.87%	18
2024 Q1	$15.4M	Buy	+103,036	New	+$17.2M	0.86%	31
2023 Q2	–	Sell	-448	Closed	-$89.7K	–	53
2023 Q1	$89.7K	Sell	448 -56,000	-99%	-$11.8M	0.01%	52
2022 Q4	$13.4M	Buy	+56,448	New	+$12M	0.8%	28
2019 Q3	–	Sell	-27,792	Closed	-$2.02M	–	75
2019 Q2	$2.02M	Sell	27,792 -78,824	-74%	-$6.05M	0.19%	58
2019 Q1	$9.96M	Buy	+106,616	New	+$8.92M	0.96%	21

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sofinnova Investments's ALNY Position: Q2 2025 in Review

Sofinnova Investments sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2025, closing a stake of 176,181 shares — an estimated $47.6M sold.

Sofinnova Investments first reported a position in ALNY in Q1 2019 and held it in 8 quarters. The position peaked at $47.6M in Q1 2025. 654 funds tracked by Wall St. Rank hold ALNY as of Q2 2025.

Sofinnova Investments reported no remaining Alnylam Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Sofinnova Investments sold 176,181 Alnylam Pharmaceuticals shares in Q2 2025, an estimated $47.6M.
Sofinnova Investments first reported a position in Alnylam Pharmaceuticals in Q1 2019 and held it in 8 quarters.
Sofinnova Investments's Alnylam Pharmaceuticals position peaked at $47.6M in Q1 2025.
654 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2025.

Based on Sofinnova Investments's 13F filing for Q2 2025, filed 14 Aug 2025.